Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes.
Yamaguchi K, Tsuchihashi K, Ueno S, Uehara K, Taguchi R, Ito M, Isobe T, Imajima T, Kitazono T, Tanoue K, Ohmura H, Akashi K, Baba E. Yamaguchi K, et al. Among authors: tsuchihashi k. ESMO Open. 2025 Jan 6;10(1):104108. doi: 10.1016/j.esmoop.2024.104108. Online ahead of print. ESMO Open. 2025. PMID: 39765187 Free article.
Effects of aging on complications following robot-assisted radical prostatectomy.
Koterazawa S, Kubota M, Sumiyoshi T, Saito R, Takaoka N, Hattori Y, Shimizu Y, Kanno T, Soda T, Okada Y, Tsuchihashi K, Sekine Y, Negoro H, Kurahashi R, Shimatani K, Sawada A, Akamatsu S, Goto T, Kobayashi T. Koterazawa S, et al. Among authors: tsuchihashi k. Int J Clin Oncol. 2024 Dec 2. doi: 10.1007/s10147-024-02660-7. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39621176
Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab.
Matsumura T, Tsuchihashi K, Yamamoto T, Jinnouchi F, Kusano W, Kusumoto Y, Arimizu K, Ohmura H, Kuma Y, Moriyama S, Yamaguchi K, Ito M, Isobe T, Ariyama H, Oda Y, Akashi K, Baba E. Matsumura T, et al. Among authors: tsuchihashi k. Intern Med. 2024 Oct 18. doi: 10.2169/internalmedicine.3743-24. Online ahead of print. Intern Med. 2024. PMID: 39428537 Free article.
Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer.
Tanoue K, Ohmura H, Uehara K, Ito M, Yamaguchi K, Tsuchihashi K, Shinohara Y, Lu P, Tamura S, Shimokawa H, Isobe T, Ariyama H, Shibata Y, Tanaka R, Kusaba H, Esaki T, Mitsugi K, Kiyozawa D, Iwasaki T, Yamamoto H, Oda Y, Akashi K, Baba E. Tanoue K, et al. Among authors: tsuchihashi k. Nat Commun. 2024 Oct 19;15(1):9033. doi: 10.1038/s41467-024-53262-w. Nat Commun. 2024. PMID: 39426955 Free PMC article.
Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.
Hirose T, Ito M, Tsuchihashi K, Ozaki Y, Nishio H, Ichihara E, Miura Y, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Endo M. Hirose T, et al. Among authors: tsuchihashi k. Int J Clin Oncol. 2024 Aug;29(8):1081-1087. doi: 10.1007/s10147-024-02572-6. Epub 2024 Jun 21. Int J Clin Oncol. 2024. PMID: 38904887
Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022.
Nozawa K, Ozaki Y, Yoshinami T, Yokoe T, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Nozawa K, et al. Among authors: tsuchihashi k. Int J Clin Oncol. 2024 Aug;29(8):1074-1080. doi: 10.1007/s10147-024-02570-8. Epub 2024 Jun 20. Int J Clin Oncol. 2024. PMID: 38900215
315 results